Development of validated methods and quantification of curcuminoids and curcumin metabolites and their pharmacokinetic study of oral administration of complete natural turmeric formulation (Cureit™) in human plasma via UPLC/ESI-Q-TOF-MS spectrometry

Molecules

Volumn 23, Issue 10, 2018, Pages

  Jude, Shintu ^a   Amalraj, Augustine ^a   Kunnumakkara, Ajaikumar B ^b   Divya, Chandradhara ^c   Löffler, Bernd Michael ^d   Gopi, Sreeraj ^a  

^a R and D Centre   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

^c Dahlia Building ^*  (India)

^d Institute of Mitochondrial Medicine   (Germany)

Author keywords

Bioavailable curcumin (Cureit ); Curcuminmetabolites; Curcuminoids; Pharmacokinetic; UPLC ESI Q TOF MS spectrometry

Indexed keywords

CURCUMIN;

ANALOGS AND DERIVATIVES; CHEMISTRY; CURCUMA; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ORAL DRUG ADMINISTRATION; PLASMA; SPECTROSCOPY; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CURCUMA; CURCUMIN; HUMANS; PLASMA; SPECTRUM ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 85053809199     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules23102415     Document Type: Article

References (28)

1. Cao, Y.; Xu, R.X.; Liu, Z. A high-throughput quantificationmethod of curcuminoids and curcuminmetabolites in human plasma via high-performance liquid chromatography/tandemmass spectrometry. J. Chromatogr. B 2014, 949, 70-78. [CrossRef] [PubMed]
2. Huang, Y.-S.; Hsieh, T.-J.; Lu, C.-Y. Simple analytical strategy for MALDI-TOF-MS and nanoUPLC-MS/MS: Quantitating curcumin in food condiments and dietary supplements and screening of acrylamide-induced ROS protein indicators reduced by curcumin. Food Chem. 2015, 174, 571-576. [CrossRef] [PubMed]
3. Anand, P.; Sundaram, C.; Jhurani, S.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin and cancer: An "old-age" disease with an "age-old" solution. Cancer Lett. 2008, 267, 133-164. [CrossRef] [PubMed]
4. Amalraj, A.; Pius, A.; Gopi, S.; Gopi, S. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives-A review. J. Tradit. Complement. Med. 2017, 7, 205-233. [CrossRef] [PubMed]
5. Dhillon, N.; Aggarwal, B.B.; Newman, R.A.; Wolff, R.A.; Kunnumakkara, A.B.; Abbruzzese, J.L.; Ng, C.S.; Badmaev, V.; Kurzrock, R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14, 4491-4499. [CrossRef] [PubMed]
6. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: Problems and promises. Mol. Pharm. 2007, 4, 807-818. [CrossRef] [PubMed]
7. Marczylo, T.H.; Steward, W.P.; Gescher, A.J. Rapid analysis of curcumin and curcumin metabolites in rat biomatrices using a novel Ultraperformance Liquid Chromatography (UPLC) method. J. Agric. Food Chem. 2009, 57, 797-803. [CrossRef] [PubMed]
8. Dempe, J.S.; Scheerle, R.K.; Pfeiffer, E.; Metzler, M. Metabolism and permeability of curcumin in cultured Caco-2 cells. Mol. Nutr. Food Res. 2013, 57, 1543-1549. [CrossRef] [PubMed]
9. Motomu, S.; Kiyotaka, N.; Akio,W.; Tsuyoshi, T.; Teiko, Y.; Shigefumi, K.; Fumiko, K.; Teruo,M. Comparison of the effects of curcumin and curcumin glucuronidein human hepatocellular carcinoma HepG2 cells. Food Chem. 2014, 151, 126-132.
10. Lou, Y.; Zheng, J.; Hu, H.; Lee, J.; Zeng, S. Application of ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry to identify curcumin metabolites produced by human intestinal bacteria. J. Chromatogr. B 2015, 985, 38-47. [CrossRef] [PubMed]
11. Asai, A.;Miyazawa, T. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci. 2000, 67, 2785-2793. [CrossRef]
12. Ireson, C.R.; Orr, S.; Jones, D.J.L.; Verschoyle, R.; Lim, C.K.; Luo, J.L.; Howells, L.; Plummer, S.M.; Jukes, R.M.; Williams Steward, W.P.; et al. Characterization of metabolites of the chemopreventive agent curcumin in humans and rat hepatocytes and in rat plasma and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001, 61, 1058-1064. [PubMed]
13. Gopi, S.; Jacob, J.; Mathur, K.Y. Acute and subchronic oral toxicity studies of hydrogenated curcuminoid formulation 'CuroWhite' in rats. Toxicol. Rep. 2016, 3, 817-825. [CrossRef] [PubMed]
14. Ireson, C.R.; Jones, D.J.; Orr, S.; Coughtrie, M.W.; Boocock, D.J.; Williams, M.L.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomark. Prev. 2002, 11, 105-111.
15. Amalraj, A.; Jude, S.; Varma, K.; Jacob, J.; Gopi, S.; Oluwafemi, O.S.; Thomas, S. Preparation of a novel bioavailable curcuminoid formulation (Cureit™) using Polar-Nonpolar-Sandwich (PNS) technology and its characterization and applications. Mater. Sci. Eng. C 2017, 75, 359-367. [CrossRef] [PubMed]
16. Gopi, S.; George, R.; Jude, S.; Sriraam, V.T. Cell culture study on the cytotoxic effects of "Cureit"-A novel bio available curcumin-anti cancer effects. J. Chem. Pharm. Res. 2014, 6, 96-100.
17. Gopi, S.; George, R.; Sriraam, V.T. Cell culture study on the effect of bioavailable curcumin-"Cureit" on elastase inhibition activity. Br. Biomed. Bull. 2014, 2, 545-549.
18. Gopi, S.; George, R.; Sriraam, V.T. Antioxidant potential of "Cureit"-A novel bioavailable curcumin formulation. Asian J. Pharm. Tech. Innov. 2014, 2, 123-127.
19. Gopi, S.; George, R.; Sriraam, V.T. Cell culture study on the effects of "Cureit" hyaluronidase inhibition-Anti aging effects. Int. J. Curr. Res. 2014, 6, 8473-8474.
20. Gopi, S.; George, R.; Thomas, M.; Jude, S. A pilot cross-over study to assess the human bioavailability of "Cureit"-A bioavailable curcumin in complete natural matrix. Asian J. Pharm. Tech. Innov. 2015, 3, 92-96.
21. Ahmad, N.; Warsi, M.H.; Iqbal, Z.; Samim, M.; Ahmad, F.J. Quantification of curcumin, demethoxycurcumin, and bisdemethoxycurcumin in rodent brain by UHPLC/ESI-Q-TOF-MS/MS after intra-nasal administration of curcuminoids loaded PNIPAM nanoparticles. Drug Test. Anal. 2014, 6, 257-267. [CrossRef] [PubMed]
22. Lin, J.K.; Pan, M.H.; Lin-Shiau, S.Y. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors 2000, 13, 153-158. [CrossRef] [PubMed]
23. Zhongfa, L.; Chiu, M.; Wang, J.; Chen, W.; Yen, W.; Fan-Havard, P.; Yee, L.D.; Chan, K.K. Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother. Pharmacol. 2012, 69, 679-689. [CrossRef] [PubMed]
24. Vareed, S.K.; Kakarala,M.; Ruffin,M.T.; Crowell, J.A.; Normolle, D.P.; Djuric, Z.; Brenner, D.E. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 1411-1417. [CrossRef] [PubMed]
25. Liu, Z.; Xie, Z.; Jones,W.; Pavlovicz, R.E.; Liu, S.; Yu, J.; Li, P.K.; Lin, J.; Fuchs, J.R.;Marcucci, G.; et al. Curcumin is a potent DNA hypomethylation agent. Bioorg. Med. Chem. Lett. 2009, 19, 706-709. [CrossRef] [PubMed]
26. Gopi, S.; Jacob, J.; Varma, K.; Jude, S.; Amalraj, A.; Arundhathy, C.A.; George, R.; Sreeraj, T.R.; Divya, C.; Kunnumakkara, A.B.; et al. Comparative Oral Absorption of Curcumin in a Natural Turmeric Matrix with Two Other Curcumin Formulations: An Open-label Parallelarm Study. Phytother. Res. 2017, 31, 1883-1891. [CrossRef] [PubMed]
27. Verma, M.K.; Najar, I.A.; Tikoo, M.K.; Singh, G.; Gupta, D.K.; Anand, R.; Khajuria, R.K.; Sharma, S.C.; Johri, R.K. Development of a validated UPLC-qTOF-MSMethod for the determination of curcuminoids and their pharmacokinetic study inmice. Daru. J. Pharm. Sci. 2013, 21, 11. [CrossRef] [PubMed]
28. Carlson, R.V.; Boyd, K.M.;Webb, D.J. The revision of the Declaration of Helsinki: Past, present and future. Br. J. Clin. Pharmacol. 2004, 57, 695-713. [CrossRef] [PubMed]